Younus Jawaid, Kligman Lynda, Jawaid M A, Dhalla Ally
Department of Medical Oncology, London Regional Cancer Program, London, ON N6A 4L6, Canada.
Department of Nursing, London Regional Cancer Program, Canada.
World J Oncol. 2013 Jun;4(3):147-150. doi: 10.4021/wjon683e. Epub 2013 Jul 15.
Mucositis is a common side effect due to chemo and/radiation therapy. Caphosol has been a proven preventive strategy against mucositis in randomized clinical trials. However, its efficacy to treat active mucositis in patients treated for solid tumors with chemotherapy is unknown. The objective was to evaluate the efficacy of Caphosol to treat mucositis by comparing the grade of mucositis before and after treatment and documenting the duration of treatment.
A retrospective review was conducted on consecutive adult patients at London Regional Cancer Program (LRCP) who developed chemotherapy-induced oral mucositis and were then treated with Caphosol. This study was approved by ethics committee at University of Western Ontario.
A total of 21 patients, two males (one with cancer esophagus and another with lung cancer) and 19 females (all with breast cancer), with a median age of 59 years were evaluated. Grade 3 mucositis was present in 4 patients who completely resolved with Caphosol in an average of 4 days of treatment, without needing any hospitalization. Fifteen patients with grade 2 mucositis reverted back to grade 0 by using Caphosol for an average of 3.5 days. One patient with no effect had grade 1 mucositis dating prior to treatment with chemotherapy and remained as such. Another patient with no initial improvement had oral candidiasis and once treated with Fluconozole and Caphosol had a complete resolution. No obvious side effects were reported by patients related to the use of Caphosol.
Our case series, for the first time, shows that Caphosol may be used as a potentially effective treatment in patients with solid tumor, who develop chemotherapy-induced mucositis.
黏膜炎是化疗和/或放疗常见的副作用。在随机临床试验中，含漱液已被证明是预防黏膜炎的有效策略。然而，其对接受化疗的实体瘤患者治疗活动性黏膜炎的疗效尚不清楚。目的是通过比较治疗前后黏膜炎的分级并记录治疗持续时间，评估含漱液治疗黏膜炎的疗效。
对伦敦地区癌症项目（LRCP）连续的成年患者进行回顾性研究，这些患者发生了化疗引起的口腔黏膜炎，随后接受含漱液治疗。本研究经西安大略大学伦理委员会批准。
共评估了21例患者，其中2例男性（1例食管癌，1例肺癌）和19例女性（均为乳腺癌），中位年龄59岁。4例患者出现3级黏膜炎，使用含漱液平均治疗4天后完全缓解，无需住院治疗。15例2级黏膜炎患者使用含漱液平均3.5天后恢复至0级。1例无效患者在化疗前为1级黏膜炎，治疗后仍为1级。另1例最初无改善的患者患有口腔念珠菌病，使用氟康唑和含漱液治疗后完全缓解。患者未报告与使用含漱液相关的明显副作用。
我们的病例系列首次表明，含漱液可能作为实体瘤患者化疗引起黏膜炎的一种潜在有效治疗方法。
